Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL

Contact: Robert Sebbag/Beth Waters
Cooney Waters Group, Inc.

Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
TAG: Aventis Pasteur statement HVTN decision

(Date:11/21/2014)... News) -- While levels of testosterone and other reproductive ... their emotional health and quality of their relationships have ... Testosterone is the main sex hormone in men. But, ... hormone, the researchers noted. The researchers analyzed data ... a long-term study of women,s health. They found that ...
(Date:11/21/2014)... /> THURSDAY, Nov. 20, 2014 (HealthDay News) -- Kidney ... can do for another. And now a new study finds ... in life are benefiting from policies that give them priority ... for almost 6,300 of the 16,900 kidney transplants that took ... information supplied by the study researchers. At the ...
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... experimental antibody drug could prove effective at lowering LDL ... with cholesterol-lowering statin medications. That,s the conclusion of ... Association annual meeting in Chicago. The drug, alirocumab, ... widely used alternative to statins, Zetia, said lead researcher ...
Breaking Medicine News(10 mins):Health News:Testosterone Plays Minor Role in Older Women's Sex Lives, Study Finds 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... THE WOODLANDS, Texas , Nov. 21, 2014 /PRNewswire/ ... announced the pricing of its previously announced underwritten public ... pursuant to an effective shelf registration statement. The offering ... a public offering price of $1.005 per share.  Lexicon ... purchase up to 7,462,687 additional shares of common stock.  ...
(Date:11/18/2014)... Nov. 18, 2014  Sanguine Biosciences – a ... and study recruitment – will use its proprietary ... help Pfizer Inc. find and recruit people diagnosed ... family members to participate in voluntary research, which ... mutations and hopefully aid in informing the development ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
Cached News: